Do Bodybuilders Use Semaglutide, and What Does the Evidence Show?

What the clinical trials tell us, and what they leave unanswered for athletes

The strongest evidence for semaglutide comes from the STEP programme. STEP 1, published in the New England Journal of Medicine, enrolled adults with a BMI of 30 or above who were not already doing structured strength training. Over 68 weeks at the 2.4 mg maintenance dose, participants lost around 15% of their body weight on average. That is a significant result, but the composition of that lost weight matters enormously if you are trying to preserve or build muscle.

Weight lost on a GLP-1 medicine is not purely fat. Studies in people with obesity show that somewhere between a quarter and a third of the weight reduction can come from lean mass, depending on protein intake, activity levels and individual response. For someone whose goal is to arrive on a competition stage with more visible muscle, that is a problem worth understanding before starting treatment, and anyone asking whether semaglutide can be used in body building will find the honest answer is that we do not have good trial data on that population, because the trials simply were not designed to answer the specific question bodybuilders are asking, which is closer to: does semaglutide help you cut fat while keeping muscle?

The physiological effects of semaglutide are well characterised in licensed use: it acts on GLP-1 receptors in the brain and gut to reduce appetite, slow the stomach emptying, and shift the body into a sustained calorie deficit. That mechanism explains the weight loss. It does not explain selective fat loss, because the medicine has no direct effect on adipocyte lipolysis or muscle protein synthesis pathways.

Why some bodybuilders are drawn to it anyway, and the risks that follow

The appeal is not hard to understand. The cutting phase of contest preparation is one of the hardest parts of the sport: sustaining a calorie deficit for months whilst keeping training volume high, managing hunger and preventing muscle breakdown. Something that blunts appetite reliably, without the stimulant side effects of older compounds, sounds useful. That is precisely why off-label interest in GLP-1 medicines has grown beyond the populations they were designed for.

The risks, though, are real. Significant muscle loss during a cut is the opposite of what physique athletes want. Severe nausea, vomiting and reduced appetite (the most common side effects reported across NHS guidance on semaglutide) can make it difficult to hit protein targets, let alone train at the intensity required to retain muscle. Side effects tend to be most pronounced around dose increases. For someone training twice a day, losing appetite to the point of not being able to eat enough protein is likely to accelerate lean mass losses rather than prevent them.

There is also the question of whether semaglutide appears on the WADA prohibited list, which is relevant to anyone competing under anti-doping rules. That question has its own dedicated answer, the short version is that its status is not fixed and changes to prohibited-substance lists are made annually, so checked, current guidance from the relevant sports body matters.

One practical note: some people looking into this around the start of a new year or before a summer cut find that timing an online consultation is easier than they expected. Ordering before 12pm on a working day means a prescriber can review the consultation the same day, the kind of detail that is easy to miss if you are planning ahead around a holiday or pay cycle.

Who semaglutide is actually licensed for, and what that means if you train

The UK licence for Wegovy (semaglutide 2.4 mg) is for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure, dyslipidaemia, prediabetes or obstructive sleep apnoea. A prescriber assesses the whole clinical picture before any treatment begins. Being a bodybuilder does not automatically disqualify someone from meeting those criteria, but it does not qualify them either, the licence and the clinical assessment are grounded in health, not aesthetic goals.

If you train regularly and are also carrying excess weight that affects your health, semaglutide may be clinically appropriate. If the primary goal is physique enhancement in someone who does not meet the BMI threshold or the weight-related condition criteria, there is no licensed route in the UK and no clinical basis for a prescriber to proceed. A thorough exploration of who semaglutide is used for and how it fits into a broader weight-management picture is a useful starting point. For the question of how semaglutide specifically intersects with bodybuilding goals and risks, there is a fuller treatment of that topic on a dedicated page.

Cost context is worth a word: private treatment pricing for semaglutide varies between providers. The cost of Wegovy in the UK covers not just the medicine but the clinical infrastructure around it, and that distinction matters for safety. A single transparent price that includes consultation, prescription and aftercare is worth more than a headline figure that omits them. If you are clinically eligible and want a prescriber to review your situation, speaking to our prescribers is the right next step.